Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy

SINTBILO® delivers over 60% LDL-C reduction in Phase 3, supporting Innovent’s China market lead.

What the company is saying

Innovent Biologics, Inc. presents SINTBILO® (tafolecimab injection) as a clinically validated, domestically developed PCSK9 antibody therapy that has achieved its primary and key secondary endpoints in a Phase 3 trial for non-familial hypercholesterolemia and mixed hyperlipidemia in China. The company highlights a >60% mean LDL-C reduction after 12 weeks, with specific figures of −65.19% (150 mg Q2W) and −64.01% (450 mg Q4W) compared to −6.61% and −4.31% for placebo, all with p-values < 0.0001. Innovent emphasizes SINTBILO®'s favorable safety profile, rapid onset of action, and comprehensive improvements in lipid parameters, including a nearly 50% reduction in Lp(a). The announcement positions SINTBILO® as the first domestically developed PCSK9 antibody therapy to be commercialized in China and notes its inclusion in the National Reimbursement Drug List effective January 1, 2025. The company claims more than 1 million patients have benefited since launch and references recommendations in multiple Chinese guidelines. Executive commentary from Professor Yida Tang and Dr. Lei Qian underscores the unmet need for non-statin therapies and the product’s evidence-based value. The tone is confident, data-driven on clinical endpoints, and promotional regarding market impact and future regulatory plans.

What the data suggests

The Phase 3 CREDIT-5 trial enrolled 198 Chinese participants, randomizing them 2:1:2:1 to tafolecimab or placebo, with 131 receiving tafolecimab and 67 placebo. Baseline mean LDL-C levels were 3.7 mmol/L (tafolecimab) and 3.8 mmol/L (placebo), with 61.1% and 53.7% having mixed dyslipidemia, and 67.9% and 79.1% at low cardiovascular risk, respectively. At week 12, tafolecimab achieved LDL-C reductions of −65.19% (150 mg Q2W) and −64.01% (450 mg Q4W), versus −6.61% and −4.31% for placebo, with all inter-group differences highly statistically significant (p < 0.0001). Key secondary endpoints—proportion of patients achieving LDL-C <2.6 mmol/L, <1.8 mmol/L, and ≥50% reduction—were also met. Additional improvements were seen in non-HDL-C, TC/HDL-C ratio, vLDL-C, ApoB, ApoB/ApoA1 ratio, and Lp(a), with Lp(a) reduced by nearly 50%. No severe or serious treatment-emergent adverse events occurred, no discontinuations due to adverse events, and no new safety signals were observed. SINTBILO® is included in China’s NRDL from January 1, 2025, and has reportedly benefited over 1 million patients, though no methodology is provided for this figure. Innovent claims over 30 strategic partnerships with an aggregate value exceeding RMB 350 billion, but no direct financial performance data or revenue figures are disclosed. The clinical data is robust and well-documented, but commercial impact and profitability remain unquantified.

Analysis

The announcement is generally positive and well-supported by detailed clinical trial data, including specific efficacy and safety results for SINTBILO® in a Phase 3 study. Most key claims about clinical outcomes are realised and substantiated with numerical evidence (e.g., LDL-C reduction, p-values, patient numbers). However, some commercial claims—such as 'benefited more than 1 million patients' and 'first domestically developed PCSK9 antibody therapy'—are asserted without supporting documentation or methodology. The forward-looking statements (e.g., plans to submit a new indication application, expectations for broader clinical impact) are clearly separated from realised results and do not dominate the narrative. There is no evidence of a large capital outlay tied to uncertain, long-term returns in this release. The main gap is the absence of any profitability or financial performance metrics, which limits the signal to weak_positive under the Disclosure Completeness Rule. The tone is somewhat promotional in referencing market leadership and patient impact, but the core clinical claims are well-evidenced.

Risk flags

• ●Commercial uptake risk remains, as the claim that SINTBILO® has benefited over 1 million patients is not supported by patient-level data or methodology, making the true scale of market penetration unverifiable.
• ●Financial transparency is limited; while the company cites over 30 partnerships valued at more than RMB 350 billion, it provides no revenue, margin, or profit figures for SINTBILO® or the broader business, leaving the financial impact of clinical success unclear.
• ●Regulatory risk persists for the planned New Indication Application to the NMPA, as approval timelines and likelihood are not specified, and future reimbursement or competitive dynamics could affect commercial outcomes.
• ●Long-term safety and real-world effectiveness are not addressed beyond the 12-week trial window, so post-market surveillance or rare adverse events could alter the risk profile.
• ●Market competition from other PCSK9 inhibitors or emerging lipid-lowering therapies could limit SINTBILO®'s growth, especially if pricing or reimbursement terms change after NRDL inclusion.

Bottom line

Innovent’s SINTBILO® demonstrates strong Phase 3 efficacy, with LDL-C reductions of over 64% and a favorable safety profile in Chinese patients with non-familial hypercholesterolemia and mixed hyperlipidemia. The drug’s inclusion in the National Reimbursement Drug List from January 2025 positions it for broad access, and the company claims over 1 million patients have already benefited, though this figure is not independently verified. While the clinical data is robust, the announcement lacks any direct financial metrics, leaving the revenue and profit impact of SINTBILO® unclear. Regulatory approval for a new indication is pending, and future commercial success will depend on actual uptake, reimbursement dynamics, and competition. Investors should focus on realized clinical outcomes and near-term reimbursement milestones, but require further disclosure on financial performance to fully assess Innovent’s equity value. The most important takeaway is that SINTBILO® is clinically validated and commercially positioned, but the scale of its financial contribution remains to be demonstrated.

Announcement summary

(HKEX:01801) Innovent Biologics, Inc. announced that its self-developed recombinant fully human anti-PCSK9 monoclonal antibody, SINTBILO® (tafolecimab injection, R&D code: IBI306), achieved its primary endpoint at week 12 in the multi-center, randomized, double-blind, placebo-controlled monotherapy Phase 3 clinical study (CREDIT-5) in Chinese participants with non-familial hypercholesterolemia and mixed hyperlipidemia. SINTBILO® monotherapy resulted in a mean LDL-C reduction of over 60% after 12 weeks of treatment with 150 mg Q2W/450 mg Q4W dosing. The study enrolled 198 participants, randomized in a 2:1:2:1 ratio to receive tafolecimab 150 mg Q2W, placebo Q2W, tafolecimab 450 mg Q4W, or placebo Q4W, following a 4-week run-in period. Of these, 131 received tafolecimab and 67 received placebo. The mean baseline LDL-C levels were 3.7 mmol/L and 3.8 mmol/L, respectively. At baseline, 61.1% and 53.7% of participants had mixed dyslipidemia, and 67.9% and 79.1% had low cardiovascular risk, in the tafolecimab and placebo groups, respectively. At week 12, the percent reduction in LDL-C from baseline in the tafolecimab group was −65.19% (150 mg Q2W) and −64.01% (450 mg Q4W), compared to −6.61% and −4.31% in the placebo groups (p-value < 0.0001). Key secondary endpoints were also achieved, with significantly higher proportions of participants in the tafolecimab groups achieving LDL-C <2.6 mmol/L, LDL-C <1.8 mmol/L, and ≥50% reduction in LDL-C from baseline, all with p-values < 0.0001. At week 12, reductions in non-HDL-C, TC/HDL-C ratio, vLDL-C, ApoB, ApoB/ApoA1 ratio, and Lp(a) were all greater in the tafolecimab groups, with Lp(a) reduced by nearly 50%. No severe or serious treatment-emergent adverse events occurred, no adverse event led to discontinuation or interruption of the study drug, and no new safety signals were observed. SINTBILO® is the first domestically developed PCSK9 antibody therapy to be commercialized in China and has been included in China's National Reimbursement Drug List, effective January 1, 2025. Since its launch, SINTBILO® has benefited more than 1 million patients and has been recommended in multiple authoritative Chinese guidelines and expert consensus statements. Innovent plans to submit a New Indication Application for SINTBILO® to China's National Medical Products Administration (NMPA) in the near future. National survey data from 2020 to 2022 showed that the prevalence of dyslipidemia among Chinese adults aged ≥18 years was 38.1%. Innovent has launched 20 products in the market, has 1 asset under NDA review, 6 assets in Phase 3 or pivotal clinical trials, and 20 more molecules in early clinical stage. Innovent has entered into more than 30 strategic partnerships with global players, representing an aggregate value of over RMB 350 billion.

Disagree with this article?